Participating in Web Summit Lisboa 2026
Expanding what is possible in cancer detection and monitoring.
DIASCI combines electrochemical biosensors with artificial intelligence to explore new ways of detecting and following aggressive cancers — a technology in development, open to partners who want to shape its next steps.
The challenge & the opportunity
Aggressive cancers demand new approaches to detection and follow-up.
Following how aggressive cancers evolve remains a scientific and clinical challenge. New, less invasive ways of reading biological signals could open room for better-informed decisions over time.
Where innovation fits
Combining biosensing and AI is an innovation path that DIASCI is building with research, intellectual property and regulatory planning — and one that investors, industry and institutions can help advance.
Context data
—
Incidence of aggressive cancers
Pending verified source
—
Current detection and monitoring gaps
Pending verified source
—
Addressable market
Pending verified source
DIONCO technology
From a blood sample to AI-supported interpretation.
A conceptual view of how the platform is designed to work. It describes the concept under development, not validated performance.
- 01
Blood sample
The analysis starts from a small blood sample.
- 02
Biomarker capture
The biosensor surface is designed to capture tumor-related biomarkers.
- 03
Electrochemical signal
Each capture event is converted into a measurable electrical signal.
- 04
AI-supported interpretation
AI models help interpret signal patterns together with other data.
In plain terms
Think of the biosensor as a highly selective listener: it reacts to specific molecules in the sample and turns that reaction into an electrical reading. The AI layer then looks for meaningful patterns in those readings — the kind of information that, once validated, could support detection and follow-up decisions.
Development hypotheses
Development hypothesis- Lower invasiveness than current approaches
- Faster turnaround of results
- Portability beyond central laboratories
These are goals under investigation, not demonstrated efficacy.
Technology Progress & Evidence
Advancing cancer detection through biosensing and AI.
DIASCI is developing a technology platform combining electrochemical biosensing and artificial intelligence to explore new possibilities in cancer detection and monitoring. Supported by preliminary research, scientific collaborations and intellectual property filings, the platform is progressing toward further validation and potential healthcare applications.
Preliminary Research Findings
Preliminary findings provide a scientific foundation for continued development and further evaluation.
Biosensing + Artificial Intelligence
Combining electrochemical biosensors with AI models to interpret biological signals and explore new diagnostic approaches.
Scientific & Clinical Collaboration
Research collaborations supporting technology development and the evaluation of potential clinical applications.
Intellectual Property
Patent applications filed in Brazil and through the international PCT system, supporting the platform's intellectual property strategy.
Explore Partnership Opportunities
Discover how DIASCI's technology could connect with your organization's innovation goals.
Scientific Foundations & Collaboration
Scientific foundations for what comes next.
DIASCI brings together expertise in biosensing, biotechnology and artificial intelligence, supported by applied research, innovation initiatives and scientific collaboration. These milestones reflect a structured development effort, while clinical and regulatory validation remains essential.
ANVISA regulatory pilot
Participation in ANVISA's pilot initiative for innovative medical devices under Public Call No. 10/2023.
Regulatory engagement — not a device registration or approval.
MCTI / RENAMA
Favorable technical assessment from Brazil's Ministry of Science, Technology and Innovation regarding DIASCI's application to join RENAMA.
A favorable opinion — formal membership still to be confirmed.
Research & scientific collaboration
Applied research and collaboration with scientific and clinical institutions.
Institutions named only after confirmation and authorization.
FAPESP & innovation initiatives
FAPESP PIPE support and innovation programs, as reported in the company portfolio.
Milestones and dates pending documentation.
Intellectual property
Patent applications in Brazil and through the international PCT system, a basis for licensing and co-development discussions.
Applications, not granted patents.
Choose your opportunity
Six ways to take part in what comes next.
Each audience has its own entry point into DIASCI's technology.
Investors
Participate in the evolution of a health deep tech.
Explore an investment opportunityPharmaceutical Industry
Explore biomarker tracking and therapy-response monitoring, in development.
Discuss a pharmaceutical partnershipLaboratories
Evaluate potential new diagnostic services and future differentiation.
Explore laboratory opportunitiesClinics & Healthcare
Investigate future detection and oncology follow-up capabilities.
Explore clinical collaborationTechnology & Innovation
Connect biosensors, AI and clinical data.
Discuss a technology partnershipResearch Institutions
Advance joint research, validation and technology transfer.
Explore research collaborationDevelopment roadmap
From research to application: progress built step by step.
DIASCI is advancing its biosensing and AI technologies through intellectual property initiatives, scientific collaboration and regulatory planning.
Milestones
2020
Project Conception
Project conceived and initially self-funded.
2022
Company Foundation
DIASCI founded and incubated at SUPERA Innovation Park in Ribeirão Preto, Brazil.
2023
Innovation and Intellectual Property
Participation in the Centelha SP program and patent application filed with Brazil's INPI.
Patent application2024
International Expansion and Collaboration
International PCT patent application, participation in ANVISA's innovative medical devices pilot, Finep Women Innovators program and ICESP collaboration.
Regulatory participation2025
Scientific Recognition and Research Advancement
Participation in the World Congress on Biosensors and FAPESP PIPE Phase 2.
2026
Scientific and Institutional Recognition
Favorable technical assessment issued by Brazil's Ministry of Science, Technology and Innovation (MCTI) regarding DIASCI's application to join RENAMA. This is not a confirmation of formal membership.
What's Next
- Strengthening scientific evidence
- Advancing clinical and technical validation
- Exploring strategic partnerships
- Evaluating future commercial applications
Awards & Recognition
Recognition of our innovation journey through national and international initiatives.
Hackathon SUS (National)
National finalist and one of the winners in Brazil's Southeast region.
NTT DATA eAwards
Finalist for the second consecutive year.
Macao Technology & Innovation Competition 2026
Finalist.
Team & clinical partners
The people behind the science.
The DIASCI team and the clinical partners who collaborate on its research.
DIASCI Team
Dr. Daniela S. Fernandes
CEO and Researcher
Dr. Cristiano C. Jayme
Researcher
Dr. Cláudia Razzino
Researcher
José Mario F. Donato
Business Consultant
Clinical Partners
Dr. Roger Chammas
Oncologist
Dr. Miyuki Uno
Biobank
Dr. Luciana Andrade
CTO, ICESP
Partners & Supporters
Join the next steps
Explore a future partnership with DIASCI.
DIASCI welcomes conversations with investors, healthcare organizations, research institutions and technology partners interested in exploring collaboration, licensing, co-development and future commercial opportunities.